pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,193 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1167Endpoints883BioPharma Dive340BioSpace303Fierce Biotech281onclive165raps104globenewswire health73
therapy area
allOncology7491Rare Disease1856Cardiology1708Immunology1472Hematology1313Vaccines1191Pulmonology
  • Experts discuss why anti-CCR8 antibody denikitug is being tested in phase 1 solid tumor trials
    Dr Bruno B. Bockorny, a gastrointestinal oncologist at Beth Israel Deaconess Medical Center and assistant professor at Harvard Medical School, explained the scientific basis for testing the anti‑CC…
    onclive · 3mo agoNeutral↗ source
  • Panel reviews clinical trial landscape and new strategies for recurrent endometrial cancer after checkpoint inhibitor failure
    A recent expert panel has examined the current state of clinical trials targeting recurrent endometrial cancer. The discussion highlighted that many patients now face disease progression after rec…
    onclive · 3mo agoNeutral↗ source
← prev
page 42 of 48
next →
fda recalls67
fda medwatch60
fda press38
1127
Psychiatry & CNS864
Ophthalmology494
Pain473
Endocrinology & Metabolism468
Infectious Disease444
Experts outline safety strategies for radiopharmaceutical treatment of advanced prostate cancer
Dr. Johann De Bono and Dr. Pedro Barata presented a discussion focused on practical methods for monitoring and managing toxicities that arise from radiopharmaceutical therapies used in metastatic c…
onclive · 3mo agoNeutral↗ source
  • Experts issue consensus guidance on lymphoma testing and treatment strategies
    Experts presented consensus recommendations for lymphoma management at the 2025 Bridging the Gaps meeting. For mantle cell lymphoma, the panel advised comprehensive testing for TP53 mutations and…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss combining radiopharmaceuticals with systemic therapies for advanced prostate cancer
    Dr. Pedro Barata and Dr. Johann de Bono presented a discussion on emerging combination strategies that pair radiopharmaceuticals with other systemic treatments for metastatic castration-resistant p…
    onclive · 3mo agoNeutral↗ source
  • Expert Answers Common Questions on Esophageal Cancer Diagnosis and Treatment
    Dr. Peter Enzinger, a recognized specialist in esophageal oncology, sits down for a clinician‑focused FAQ interview that tackles the most frequently asked questions about the disease. The conversa…
    onclive · 3mo agoNeutral↗ source
  • Oncologist Charles Blanke reflects on cancer research journey and push for medical aid in dying
    The latest episode of the "How This Is Building Me" podcast features D. Ross Camidge, MD, PhD, speaking with Charles D. Blanke, MD, a professor at Oregon Health & Science University. The conversati…
    onclive · 3mo agoPositive↗ source
  • FDA approves vepdegestrant for ESR1-mutated ER-positive advanced breast cancer
    On May 1, 2026 the FDA gave its first approval to vepdegestrant, an oral selective estrogen receptor degrader, for adult patients with estrogen receptor-positive, HER2-negative breast cancer that c…
    onclive · 3mo agoApprovalPositive↗ source
  • FDA chief Marty Makary resigns, ending turbulent tenure
    FDA chief Marty Makary has resigned, ending a tenure described as turbulent with leadership upheaval, mass layoffs, political pressure and public disputes with drugmakers. President Trump announce…
    BioPharma Dive · 3mo agoRegulatoryNegative↗ source
  • Bristol Myers Squibb and China's Hengrui Pharma launch $15.2 billion alliance covering up to 13 early-stage drugs
    Bristol Myers Squibb announced a new partnership with Chinese drugmaker Hengrui Pharma that could be worth more than $15.2 billion and includes up to 13 early-stage drug candidates. The deal refle…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • Pain drug research gains momentum a year after Vertex launch as new startups revive sodium channel targets
    A year after Vertex introduced its breakthrough pain medication, the field of pain drug development is at a pivotal crossroads. Analysts note that renewed scientific focus and investor interest are…
    BioPharma Dive · 3mo agoPositive↗ source
  • Arvinas and Pfizer license newly approved PROTAC breast cancer drug Veppanu to Rigel Pharmaceuticals
    Arvinas and Pfizer have signed a licensing agreement that transfers ownership of their newly approved breast cancer drug, Veppanu, to San Francisco‑based Rigel Pharmaceuticals. The deal gives Arvi…
    BioPharma Dive · 3mo agoDealPositive↗ source
  • FDA grants breakthrough therapy designation to Emi-Le for advanced adenoid cystic carcinoma
    The U.S. Food and Drug Administration has granted breakthrough therapy designation to Emi-Le for patients with locally advanced, recurrent or metastatic adenoid cystic carcinoma (ACC). Phase 1 tri…
    onclive · 3mo agoCRLPositive↗ source
  • Phase 1 trial shows safety and early PSA responses for novel PSMA radioligand in mCRPC
    A Phase 1 study evaluated the long‑circulating PSMA therapeutic radioligand [177Lu]Lu‑D‑Dan‑Phe‑PSMA in patients with metastatic castration‑resistant prostate cancer. The trial enrolled several dos…
    onclive · 3mo agoPositive readoutPositive↗ source
  • FDA warns of secondary cancers linked to tazemetostat in follicular lymphoma and epithelioid sarcoma
    The FDA issued an alert after the voluntary withdrawal of tazemetostat indications for follicular lymphoma and epithelioid sarcoma, emphasizing the drug's association with secondary primary maligna…
    onclive · 3mo agoRegulatoryNegative↗ source
  • Immunotherapy trials like PODIUM-303 are reshaping treatment for squamous cell anal cancer, says Dr Parikh
    Dr Aparna R. Parikh, an oncologist at Massachusetts General Hospital and Harvard professor, highlighted the growing feasibility of immunotherapy studies in squamous cell anal carcinoma (SCAC). She…
    onclive · 3mo agoPositive↗ source
  • Honesty and Humor Offer Hope in Breast Cancer Survivorship, Says Dr Nunnery and Survivor Annie Bond
    The Breast Cancer Briefing podcast, hosted by Dr Sara Nunnery of Tennessee Oncology, featured a conversation with Annie Bond, a breast cancer survivor and patient advocate. Bond, who was first dia…
    onclive · 3mo agoPositive↗ source
  • Fox Chase Cancer Center and Labcorp launch study of ultra-sensitive blood test for early-stage lung cancer recurrence
    Fox Chase Cancer Center and Labcorp announced a new clinical trial to evaluate a tumor-informed, whole-genome sequencing ctDNA minimal residual disease (MRD) assay for early-stage non-small cell lu…
    onclive · 3mo agoPositive↗ source
  • Experts highlight unmet needs and emerging role of antibody drug conjugates in endometrial cancer
    Experts note that significant unmet needs persist in endometrial cancer even as antibody drug conjugates (ADCs) begin to expand treatment options. They suggest ADCs could address gaps in recurrent…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss emerging therapies shaping the future of relapsed and refractory multiple myeloma
    In a recent opinion segment, Dr. Ajay Nooka and Dr. Noopur Raje explore how new treatments and ongoing trials are influencing the landscape for patients with relapsed and refractory multiple myelom…
    onclive · 3mo agoNeutral↗ source
  • Experts discuss emerging MET-driven resistance data shaping second-line therapy for EGFR-mutated lung cancer
    In a recent video segment, Dr. Jacob Sands sits down with Dr. Heather Wakelee to talk about the impact of new findings on MET-driven resistance in EGFR‑mutated non‑small cell lung cancer. The conv…
    onclive · 3mo agoNeutral↗ source
  • Sequencing antibody-drug conjugates adds complexity to recurrent endometrial cancer treatment
    Therapy sequencing for recurrent endometrial cancer is becoming increasingly complex as immunotherapy moves earlier in the treatment pathway and antibody-drug conjugates (ADCs) gain traction. Expe…
    onclive · 3mo agoNeutral↗ source
  • Experts highlight need for broader monitoring in polycythemia vera as patient shows disease progression despite controlled hematocrit
    A 68-year‑old woman with a six‑year history of polycythemia vera (PV) and prior deep‑vein thrombosis has kept her hematocrit below 45% on hydroxyurea, indicating good control of that metric. Desp…
    onclive · 3mo agoNeutral↗ source
  • AUA and SUO Issue 2026 Update to Advanced Prostate Cancer Guideline
    The American Urological Association (AUA) and the Society of Urologic Oncology (SUO) have released an amendment to their Advanced Prostate Cancer Guideline for 2026. The update revises recommendat…
    onclive · 3mo agoNeutral↗ source
  • Delayed and re-emergent immune-related adverse events can persist years after melanoma checkpoint therapy, says expert
    Dr. Michael A. Postow, chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center, explained that immune checkpoint inhibitors (ICIs) for melanoma have a distinct toxicity profile comp…
    onclive · 3mo agoNeutral↗ source